GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

June 15, 2018: By Jon Swedien

GenSight Biologics will continue to pursue US and European regulatory approvals for its gene therapy candidate for Leber hereditary optic neuropathy (LHON) despite missing a primary endpoint in a Phase III trial, CEO Bernard Gilly said June 12.

The candidate, GS010 (rAAV2/2-ND4), improved subjects’ vision during the REVERSE trial but missed the primary endpoint because it failed to outperform the sham.

Paris-based GenSight said it is encouraged by the results, and it has other clinical trials for GS010 in progress.

“We are now going to discuss the full results with regulatory authorities so that we are aligned on how best to bring GS010 to market with our existing Phase III program within our defined timelines,” Gilly said.

REVERSE evaluated a single intravitreal injection of GS010 in 37 subjects who lost vision due to LHON between six and 12 months prior to the beginning of the study.

Subjects received GS010 in one randomly selected eye and sham treatment (pressure to the eye using the blunt end of a syringe) in the other.

Treated eyes improved +11 ETDRS letters at 48 weeks compared with baseline, while untreated eyes improved +10 ETDRS letters, the company said.

The data from REVERSE suggest that GS010 may provide meaningful bilateral improvement of vision, which GenSight had not expected, Chief Medical Officer Barrett Katz said.

Katz said GS010-treated eyes were significantly more likely to achieve vision of 20/200 or better when compared with eyes treated with the sham.

He said there could be a potentially larger benefit for subjects at earlier stages of the disease.

GenSight said the gene therapy met some secondary endpoints, specifically the change in ganglion cell layer macular volume measured from baseline to week 48 and change in thickness of the temporal quadrant of the retinal nerve fiber layer from baseline to week 48.

These results demonstrated a direct biologic and physiological impact of GS010 on the anatomy relevant to LHON, GenSight said.

Also, contrast sensitivity, as determined by Pelli-Robson low‑vision testing, almost doubled in the GS010‑treated eyes compared to sham‑treated eyes.

GenSight noted that subjects who were age 21 and younger at enrollment tended to have better clinical outcomes.

The company said all 37 subjects will be evaluated again at 96 weeks. That data will be reported in Q1-2019.

GS010 is also being investigated in two additional ongoing Phase III trials—RESCUE and REFLECT.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility